| Size | Price | |
|---|---|---|
| 250mg | ||
| Other Sizes |
| Targets |
Methyl 3-hydroxy-4,5-dimethoxybenzoate targets bacterial cells and oxidative stress pathways. It shows significant antibacterial effects against various bacterial strains. It also exhibits antioxidant activity in the presence of H2O2. Its mechanism of action likely involves disruption of bacterial cell walls and scavenging of free radicals.
|
|---|---|
| ln Vitro |
In vitro, methyl 3-hydroxy-4,5-dimethoxybenzoate exhibits significant antibacterial effects and antioxidant activity. Its minimum inhibitory concentration (MIC) is 5 mg/ml against Staphylococcus aureus and Rhizopus, and 10 mg/ml against E. coli. It shows antioxidant activity in the presence of H2O2. Its activity is concentration-dependent, with effective concentrations in the mg/mL range. Its antibacterial and antioxidant activities make it a valuable tool for studying natural product pharmacology.
|
| ln Vivo |
In vivo, methyl 3-hydroxy-4,5-dimethoxybenzoate has not been extensively studied as a therapeutic agent. Its antibacterial and antioxidant activities may have therapeutic potential. However, detailed in vivo efficacy data and pharmacokinetic profiles are limited in publicly available sources.
|
| Enzyme Assay |
The in vitro antibacterial activity assay for methyl 3-hydroxy-4,5-dimethoxybenzoate typically uses broth microdilution or agar diffusion methods against bacterial strains. The compound is dissolved in suitable solvent and diluted in culture medium at varying concentrations (typically 1 to 10 mg/mL). The minimum inhibitory concentration (MIC) is determined. For antioxidant assays, the compound is tested for its ability to scavenge free radicals or protect cells from H2O2-induced oxidative stress.
|
| Cell Assay |
For in vitro cellular assays, bacterial cultures or mammalian cells are treated with methyl 3-hydroxy-4,5-dimethoxybenzoate at concentrations ranging from 1 to 10 mg/mL for 24-72 hours. Bacterial growth inhibition is assessed by measuring optical density. Cell viability is assessed using MTT or CellTiter-Glo assays. All experiments include appropriate controls and are performed in triplicate.
|
| Animal Protocol |
For in vivo studies, methyl 3-hydroxy-4,5-dimethoxybenzoate may be administered to rodents via oral gavage or intraperitoneal injection. However, specific in vivo protocols are not well-documented.
|
| ADME/Pharmacokinetics |
The pharmacokinetic properties of methyl 3-hydroxy-4,5-dimethoxybenzoate have not been extensively characterized. The compound has a molecular weight of 212.2. Following oral administration, it is expected to have moderate absorption.
|
| Toxicity/Toxicokinetics |
Preclinical toxicology studies of methyl 3-hydroxy-4,5-dimethoxybenzoate are limited. In acute toxicity studies, the compound is tolerated at moderate doses.
|
| References | |
| Additional Infomation |
Methyl 3-hydroxy-4,5-dimethoxybenzoate is a gallic acid analogue extracted from pine flower and bayberry. It has a molecular formula of C10H12O5 and a molecular weight of 212.2. It exhibits significant antibacterial and antioxidant activities. It is not approved for human use and is intended for research purposes only.
|
| Molecular Formula |
C10H12O5
|
|---|---|
| Molecular Weight |
212.19928
|
| Exact Mass |
212.068
|
| CAS # |
83011-43-2
|
| PubChem CID |
2733956
|
| Appearance |
White to off-white solid powder
|
| Density |
1.2±0.1 g/cm3
|
| Boiling Point |
366.6±37.0 °C at 760 mmHg
|
| Melting Point |
80-84 °C
|
| Flash Point |
144.8±20.0 °C
|
| Vapour Pressure |
0.0±0.9 mmHg at 25°C
|
| Index of Refraction |
1.525
|
| LogP |
1.66
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
5
|
| Rotatable Bond Count |
4
|
| Heavy Atom Count |
15
|
| Complexity |
218
|
| Defined Atom Stereocenter Count |
0
|
| InChi Key |
LCIFXEQPXQVBGL-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C10H12O5/c1-13-8-5-6(10(12)15-3)4-7(11)9(8)14-2/h4-5,11H,1-3H3
|
| Chemical Name |
methyl 3-hydroxy-4,5-dimethoxybenzoate
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 4.7125 mL | 23.5627 mL | 47.1254 mL | |
| 5 mM | 0.9425 mL | 4.7125 mL | 9.4251 mL | |
| 10 mM | 0.4713 mL | 2.3563 mL | 4.7125 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
